StockData
Electra Therapeutics, Inc. logo

Electra Therapeutics, Inc. (ETRA) company profile

ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$8.35+0.04 (+0.48%)

Close on Nov 17, 2026Market cap $524.94MP/E –Yield –

About Electra Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Electra Therapeutics, Inc. is listed on Nasdaq under the ticker ETRA, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Electra Therapeutics, Inc.
Headquarters
South San Francisco, CA
Address
230 East Grand Avenue, Suite S-100 94080
Phone
(888) 743-2290
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
ETRA
Exchange
Nasdaq
IPO date
Sep 18, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2088082
CUSIP
284825106
ISIN
US2848251060
FIGI
BBG012QDV1C7
Share class FIGI
BBG012QDV1D6
EIN
83-2193635

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Quehuong (Kathy) DongPresident & CEO, Director455,484
Gary S. KoeChief Technical Officer63,656
Graham ParryChief Scientific Officer85,504
David J. TuckerPrincipal Accounting Officer–
Christopher William ClarkChief Financial Officer–
Kim-Hien DaoChief Medical Officer–
Carl L. GordonDirector2,194,579
Genesis GP LLC OrbiMedDirector–
Capital GP VII LLC OrbiMedDirector5,126,891
Advisors Llc OrbimedDirector2,194,579
Nancy StaglianoDirector255,635
Matthew K. FustDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 18, 2026
Offer price
$15.00
Securities offered
23,333,334
Gross proceeds
$350.00M
Exchange
Nasdaq
First trading day
Sep 18, 2026
First-day close
$13.25-11.7%
Lock-up ends (est.)
Mar 17, 2027

“The initial public offering price is $15.00 per share of our common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?